Tempest receives clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hcc in china

Brisbane, calif., june 30, 2025 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the national medical products administration (nmpa) in china to proceed with a pivotal trial to evaluate amezalpat (tpst-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc).
HCC Ratings Summary
HCC Quant Ranking